Key facts
- Notable investors include Tech Incubator Program for Startup, Center for Creative Economy and Innovation, JB Investment (Seoul), JNP Global, Reventures — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Mediark
- ·The full record, as it builds
Funding rounds
No funding rounds for Mediark are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Mediark
Developer of a biopharmaceutical delivery platform intended to caters biomaterials and pharmaceutical businesses. The company's platform provides porous source materials and customized biopharmaceutical particles by designing metal combinations optimized for immune activity cell regeneration, enabling chemical and biotechnology businesses to use in them for applications like adsorption, catalysis, drug delivery, and pharmaceutical development.
- Sector
- Healthcare
- HQ
- Cheongju, South Korea
- Founded
- 2022
- Employees
- 10
- Website
- mediark.kr/
- Ownership
- Privately Held (backing)
Mediark doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Mediark shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Mediark in its N-PORT filings yet. We sweep new filings monthly.